US launch for Xenazine
This article was originally published in Scrip
Executive Summary
Ovation Pharmaceuticalshas launched Xenazine (tetrabenazine) in the US, making it the first product for the treatment of chorea in Huntington's disease to be made available there. The product has a wholesale acquisition cost of about $3,000 for a 12mg bottle and $6,000 for 25mg, which gives an annual price of between $30,000 and $50,000 depending on the individual patient's needs, Ovation says. It will be marketed by Ovation's 48-person sales force to specialists in CNS disorders, and the company is offering a financial patient support programme for those in need.